Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: A randomized controlled trial | Zendy

Avijit Hazra | Zendy; Sonal Pande | Zendy; AnupKumar Kundu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: A randomized controlled trial

Author(s) -

Avijit Hazra,

Sonal Pande,

AnupKumar Kundu

Publication year - 2014

Publication title -

indian journal of pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.286

H-Index - 59

eISSN - 1998-3751

pISSN - 0253-7613

DOI - 10.4103/0253-7613.144912

Subject(s) - silodosin , tamsulosin , medicine , international prostate symptom score , urology , lower urinary tract symptoms , sexual function , randomized controlled trial , prostate , hyperplasia , cancer

Benign prostatic hyperplasia (BPH) is the most common cause of lower urinary tract symptoms in elderly men. Selective alfa1-adrenergic antagonists are now first-line drugs in the medical management of BPH. We conducted a single-blind, parallel group, randomized, controlled trial to compare the effectiveness and safety of the new alfa1-blocker silodosin versus the established drug tamsulosin in symptomatic BPH.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research